Cargando…

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment

Immune thrombocytopenia (ITP) is now well‐known to reduce patients' health‐related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I‐WISh (ITP W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Nichola, Kruse, Alexandra, Kruse, Caroline, Watson, Shirley, Morgan, Mervyn, Provan, Drew, Ghanima, Waleed, Arnold, Donald M., Tomiyama, Yoshiaki, Santoro, Cristina, Michel, Marc, Laborde, Serge, Lovrencic, Barbara, Hou, Ming, Bailey, Tom, Taylor‐Stokes, Gavin, Haenig, Jens, Bussel, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898610/ https://www.ncbi.nlm.nih.gov/pubmed/33170956 http://dx.doi.org/10.1002/ajh.26045

Ejemplares similares

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life
por: Cooper, Nichola, et al.
Publicado: (2020)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
por: Viana, Ricardo, et al.
Publicado: (2021)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
por: Chakrabarti, Prantar, et al.
Publicado: (2022)

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)
por: González-López, Tomás José, et al.
Publicado: (2022)

Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?
por: MacWhirter - DiRaimo, Jennifer, et al.
Publicado: (2021)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

COVID-19 Vaccination in Adults with Immune Thrombocytopenia (ITP): Data from the Platelet Disorder Support Association (PDSA) Patient Registry
por: MacWhirter - DiRaimo, Jennifer, et al.
Publicado: (2021)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
por: Doobaree, Indraraj Umesh, et al.
Publicado: (2019)

COVID-19 Vaccination in Children and Young Adults with Pre-Existing Immune Thrombocytopenia (ITP): Preliminary Data from the Platelet Disorder Support Association (PDSA) Patient Registry
por: MacWhirter - DiRaimo, Jennifer, et al.
Publicado: (2022)

Patient and Physician Perspectives in the Management of Immune Thrombocytopenia in Iran: Responses from the ITP World Impact Survey (I-WISh)
por: Eshghi, Peyman, et al.
Publicado: (2023)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

Japanese and French translation and linguistic validation of a patient-reported outcome tool to assess quality of life in patients with Immune Thrombocytopenia (ITP): the ITP Life Quality Index (ILQI)
por: Tomiyama, Yoshiaki, et al.
Publicado: (2022)

P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS
por: Ghanima, W., et al.
Publicado: (2022)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

P1637: RISKS FOR A PLATELET COUNT DROP: COVID-19 & ITP DATA FROM THE PLATELET DISORDER SUPPORT ASSOCIATION (PDSA) PATIENT REGISTRY
por: DiRaimo, J., et al.
Publicado: (2022)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017)

The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
por: Hughes, David
Publicado: (2022)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

PB2620: NIGHTTIME SYMPTOMS ARE ASSOCIATED WITH FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto’s Thyroiditis: Role of Levothyroxine in Improving the Clinical Outcome of ITP
por: Tahir, Hassan, et al.
Publicado: (2016)

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP
por: Jawed, Muzamil, et al.
Publicado: (2021)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease
por: Priest, David H., et al.
Publicado: (2017)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group
por: Mingot-Castellano, M. Eva, et al.
Publicado: (2019)

Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
por: Kuter, David J., et al.
Publicado: (2023)

The Role of Leptin in Childhood Immune Thrombocytopenia (ITP): An Anti-Inflammatory Agent?
por: Thomas, Iason, et al.
Publicado: (2021)

Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives
por: Zitek, Tony, et al.
Publicado: (2022)

Reticulated Platelet Count as a Diagnostic Tool in Immune Thrombocytopenia (ITP)
por: Butt, Aqsa Javed, et al.
Publicado: (2023)

Current Management of Primary Immune Thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2015)

Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
por: Cuker, Adam, et al.
Publicado: (2023)

Recent advances in the mechanisms and treatment of immune thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nuresnlo9fpgfb5aq5omcjt5pe